Effect of melittin on metabolomic profile and cytokine production in PMA-differentiated THP-1 cells

Alqarni, Abdulmalik M. and Ferro, Valerie A. and Parkinson, John A. and Dufton, Mark J. and Watson, David G. (2018) Effect of melittin on metabolomic profile and cytokine production in PMA-differentiated THP-1 cells. Vaccines, 6 (4). 72. ISSN 2076-393X (https://doi.org/10.3390/vaccines6040072)

[thumbnail of Alqarni-etal-Vaccines-2018-Effect-of-melittin-on-metabolomic-profile-and-cytokine-production]
Preview
 Text. Filename: Alqarni_etal_Vaccines_2018_Effect_of_melittin_on_metabolomic_profile_and_cytokine_production.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (3MB)| Preview

Abstract

Melittin, the major active peptide of honeybee venom (BV), has potential for use in adjuvant immunotherapy. The immune system response to different stimuli depends on the secretion of different metabolites from macrophages. One potent stimulus is lipopolysaccharide (LPS), a component isolated from gram-negative bacteria, which induces the secretion of pro-inflammatory cytokines in macrophage cell cultures. This secretion is amplified when LPS is combined with melittin. In the present study, pure melittin was isolated from whole BV by flash chromatography to obtain pure melittin. The ability of melittin to enhance the release of tumour necrosis factor-α (TNF-α), Interleukin (IL-1β, IL-6, and IL-10) cytokines from a macrophage cell line (THP-1) was then assessed. The response to melittin and LPS, applied alone or in combination, was characterised by metabolic profiling, and the metabolomics results were used to evaluate the potential of melittin as an immune adjuvant therapy. The addition of melittin enhanced the release of inflammatory cytokines induced by LPS. Effective chromatographic separation of metabolites was obtained by liquid chromatography-mass spectrometry (LC-MS) using a ZIC-pHILIC column and an ACE C4 column. The levels of 108 polar and non-polar metabolites were significantly changed (p ˂ 0.05) following cell activation by the combination of LPS and melittin when compared to untreated control cells. Overall, the findings of this study suggested that melittin might have a potential application as a vaccine adjuvant.

ORCID iDs

Alqarni, Abdulmalik M., Ferro, Valerie A. ORCID logoORCID: https://orcid.org/0000-0003-1967-3603, Parkinson, John A. ORCID logoORCID: https://orcid.org/0000-0003-4270-6135, Dufton, Mark J. ORCID logoORCID: https://orcid.org/0000-0001-8176-2194 and Watson, David G. ORCID logoORCID: https://orcid.org/0000-0003-1094-7604;
CORE (COnnecting REpositories)